Dr. Adam Brufsky, MD

Claim this profile

University of Pittsburgh Cancer Institute (UPCI)

Expert in Breast Cancer
Studies Cancer
31 reported clinical trials
70 drugs studied

Area of expertise

1Breast Cancer
Global Leader
Adam Brufsky, MD has run 29 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
Stage III
2Cancer
Adam Brufsky, MD has run 10 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative

Affiliated Hospitals

Image of trial facility.
University Of Pittsburgh Cancer Institute (UPCI)
Image of trial facility.
University Of Pittsburgh Medical Center

Clinical Trials Adam Brufsky, MD is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria

More about Adam Brufsky, MD

Clinical Trial Related1 year of experience running clinical trials · Led 31 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Adam Brufsky, MD has experience with
  • Paclitaxel
  • Trastuzumab
  • Abemaciclib
  • Pertuzumab
  • Olaparib
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam Brufsky, MD specialize in?
Adam Brufsky, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Adam Brufsky, MD currently recruiting for clinical trials?
Yes, Adam Brufsky, MD is currently recruiting for 9 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Adam Brufsky, MD has studied deeply?
Yes, Adam Brufsky, MD has studied treatments such as Paclitaxel, Trastuzumab, Abemaciclib.
What is the best way to schedule an appointment with Adam Brufsky, MD?
Apply for one of the trials that Adam Brufsky, MD is conducting.
What is the office address of Adam Brufsky, MD?
The office of Adam Brufsky, MD is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.